- Home
- PSBD vs CVRX Comparison
PSBD vs CVRX Comparison
Compare PSBD & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- CVRX
- Stock Information
- Founded
- PSBD 2009
- CVRX 2000
- Country
- PSBD United States
- CVRX United States
- Employees
- PSBD N/A
- CVRX N/A
- Industry
- PSBD
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PSBD
- CVRX Health Care
- Exchange
- PSBD Nasdaq
- CVRX Nasdaq
- Market Cap
- PSBD 519.7M
- CVRX 419.8M
- IPO Year
- PSBD 2024
- CVRX 2021
- Fundamental
- Price
- PSBD $15.80
- CVRX $17.62
- Analyst Decision
- PSBD Buy
- CVRX Strong Buy
- Analyst Count
- PSBD 7
- CVRX 7
- Target Price
- PSBD $16.93
- CVRX $17.00
- AVG Volume (30 Days)
- PSBD 17.7K
- CVRX 213.8K
- Earning Date
- PSBD 02-08-2025
- CVRX 01-27-2025
- Dividend Yield
- PSBD 12.02%
- CVRX N/A
- EPS Growth
- PSBD N/A
- CVRX N/A
- EPS
- PSBD N/A
- CVRX N/A
- Revenue
- PSBD N/A
- CVRX $47,255,000.00
- Revenue This Year
- PSBD N/A
- CVRX $31.78
- Revenue Next Year
- PSBD N/A
- CVRX $26.42
- P/E Ratio
- PSBD N/A
- CVRX N/A
- Revenue Growth
- PSBD N/A
- CVRX 34.38
- 52 Week Low
- PSBD $15.12
- CVRX $6.40
- 52 Week High
- PSBD $17.12
- CVRX $29.23
- Technical
- Relative Strength Index (RSI)
- PSBD 54.56
- CVRX 76.79
- Support Level
- PSBD $15.17
- CVRX $13.82
- Resistance Level
- PSBD $16.07
- CVRX $17.72
- Average True Range (ATR)
- PSBD 0.41
- CVRX 0.88
- MACD
- PSBD 0.05
- CVRX 0.49
- Stochastic Oscillator
- PSBD 71.58
- CVRX 98.09
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.